Pliant Therapeutics Inc (PLRX)

$1.26 +0.06 (5.00%)
Market Cap 77.35M
Revenue (ttm) 0.00
Net Income (ttm) -210.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,120,900
Avg Vol 1,170,766
Day's Range N/A - N/A
Shares Out 61.39M
Stochastic %K 43%
Beta 1.30
Analysts Sell
Price Target $4.79

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
Fib7867
Fib7867 Jul. 4 at 2:35 AM
#myPLRXanalysis $PLRX
0 · Reply
Bellbent
Bellbent Jul. 3 at 5:58 PM
$PLRX what an amazing time to sell a company! Too bad management is holding shareholders hostage after they sold their shares at an all time high and rape the company with huge wages! When you have to initiate a poison pill to save your job as a multi millionaire you are scum IMO. https://www.cnbc.com/2025/07/03/trump-big-beautiful-bill-top-five-tax-changes-for-the-wealthy.html
0 · Reply
Golibajje
Golibajje Jul. 1 at 3:48 PM
$PLRX hold it strongly! Over $4+ cash.. look at also $INAB.. only 2.7m public float.. treating difficult types of brain cancer.. can run like $LYRA over 500% when they report topline data anytime from now!! $GOSS $BGLC
0 · Reply
wwmeinc
wwmeinc Jul. 1 at 3:36 PM
$GOSS ....I see $PLRX has officially thrown in the 'towel' on their IPF drug under development(unfortunate for all...truly...a real killer disease to have....barring lung transplants as a last resort).....I bring this up...as Seralutinib has shown some benefit in IPF....not our main goal(s) for sure...but anything that helps is worth a long, strong look in my books...Pliant is moving forward with their solid lung cancer drug.....w/Keytruda thrown in...that Merck ... $MRK ...they do seem to pop-up in more than a few of the cancer news ;) Keytruda....very fortunate to have around for all patients though....Good trading...glta "CONCLUSIONS: Seralutinib demonstrated dose-dependent anti-fibrotic effects in two models of human pulmonary fibrosis. These data, along with TORREY circulating fibrotic biomarker data, suggest that seralutinib may have therapeutic effects on the fibrotic pathways underlying both WHO Group 1 and Group 3 PH." https://journal.chestnet.org/article/S0012-3692(24)04264-8/fulltext#:~:text=CONCLUSIONS:%20Seralutinib%20demonstrated%20dose%2Ddependent,1%20and%20Group%203%20PH.
0 · Reply
Harunkaraca
Harunkaraca Jul. 1 at 2:14 PM
$PLRX
0 · Reply
Golibajje
Golibajje Jul. 1 at 2:08 PM
$PLRX hope Tang capital buys this for $4+ (at least at cash position) and fire all the as*holes from mgmt
0 · Reply
ikkydiphoenix
ikkydiphoenix Jul. 1 at 1:55 PM
$PLRX back in at 1.14
0 · Reply
Quantumup
Quantumup Jul. 1 at 12:10 PM
Cantor🏁 $TRVI Overweight-$25 and said, "We are initiating coverage of $TRVI with an OW rating and $25 PT, representing ~300% upside from current levels." $PLRX $RHHBY Cantor added, "This is about as high conviction a call as we'll ever have for a pre-commercial program." Cantor went on to say:
1 · Reply
Harunkaraca
Harunkaraca Jun. 30 at 7:50 PM
$PLRX
0 · Reply
arribaStocktrading
arribaStocktrading Jun. 30 at 3:11 PM
$PLRX Picked up 5000 @ 1.19. The demise of bexotegrast should have been highly anticipated. I'm down slightly as I type this but expect the ship will soon right itself.
2 · Reply
Latest News on PLRX
Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 8 days ago

Pliant Therapeutics Provides Update on BEACON-IPF

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025, 4:03 PM EDT - 6 weeks ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 2 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025, 4:05 PM EDT - 2 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 7, 2025, 4:05 PM EDT - 3 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Pliant Therapeutics: An Activist On Deck

Apr 3, 2025, 12:22 PM EDT - 3 months ago

Pliant Therapeutics: An Activist On Deck

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 17, 2025, 8:00 AM EDT - 3 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 11:04 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 13, 2025, 7:20 AM EDT - 4 months ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 1:32 PM EST - 4 months ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 3, 2025, 9:27 AM EST - 4 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 26, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 25, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 24, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 4 months ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 21, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 3:39 PM EST - 4 months ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Feb 19, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Feb 18, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation

Feb 17, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out

Feb 16, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out

Feb 14, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out

Fib7867
Fib7867 Jul. 4 at 2:35 AM
#myPLRXanalysis $PLRX
0 · Reply
Bellbent
Bellbent Jul. 3 at 5:58 PM
$PLRX what an amazing time to sell a company! Too bad management is holding shareholders hostage after they sold their shares at an all time high and rape the company with huge wages! When you have to initiate a poison pill to save your job as a multi millionaire you are scum IMO. https://www.cnbc.com/2025/07/03/trump-big-beautiful-bill-top-five-tax-changes-for-the-wealthy.html
0 · Reply
Golibajje
Golibajje Jul. 1 at 3:48 PM
$PLRX hold it strongly! Over $4+ cash.. look at also $INAB.. only 2.7m public float.. treating difficult types of brain cancer.. can run like $LYRA over 500% when they report topline data anytime from now!! $GOSS $BGLC
0 · Reply
wwmeinc
wwmeinc Jul. 1 at 3:36 PM
$GOSS ....I see $PLRX has officially thrown in the 'towel' on their IPF drug under development(unfortunate for all...truly...a real killer disease to have....barring lung transplants as a last resort).....I bring this up...as Seralutinib has shown some benefit in IPF....not our main goal(s) for sure...but anything that helps is worth a long, strong look in my books...Pliant is moving forward with their solid lung cancer drug.....w/Keytruda thrown in...that Merck ... $MRK ...they do seem to pop-up in more than a few of the cancer news ;) Keytruda....very fortunate to have around for all patients though....Good trading...glta "CONCLUSIONS: Seralutinib demonstrated dose-dependent anti-fibrotic effects in two models of human pulmonary fibrosis. These data, along with TORREY circulating fibrotic biomarker data, suggest that seralutinib may have therapeutic effects on the fibrotic pathways underlying both WHO Group 1 and Group 3 PH." https://journal.chestnet.org/article/S0012-3692(24)04264-8/fulltext#:~:text=CONCLUSIONS:%20Seralutinib%20demonstrated%20dose%2Ddependent,1%20and%20Group%203%20PH.
0 · Reply
Harunkaraca
Harunkaraca Jul. 1 at 2:14 PM
$PLRX
0 · Reply
Golibajje
Golibajje Jul. 1 at 2:08 PM
$PLRX hope Tang capital buys this for $4+ (at least at cash position) and fire all the as*holes from mgmt
0 · Reply
ikkydiphoenix
ikkydiphoenix Jul. 1 at 1:55 PM
$PLRX back in at 1.14
0 · Reply
Quantumup
Quantumup Jul. 1 at 12:10 PM
Cantor🏁 $TRVI Overweight-$25 and said, "We are initiating coverage of $TRVI with an OW rating and $25 PT, representing ~300% upside from current levels." $PLRX $RHHBY Cantor added, "This is about as high conviction a call as we'll ever have for a pre-commercial program." Cantor went on to say:
1 · Reply
Harunkaraca
Harunkaraca Jun. 30 at 7:50 PM
$PLRX
0 · Reply
arribaStocktrading
arribaStocktrading Jun. 30 at 3:11 PM
$PLRX Picked up 5000 @ 1.19. The demise of bexotegrast should have been highly anticipated. I'm down slightly as I type this but expect the ship will soon right itself.
2 · Reply
niram7
niram7 Jun. 30 at 10:00 AM
$PLRX This is a old news, was allreay published in march, when the stock price droped 55%. I dont understand why shorts get excited.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 30 at 9:33 AM
WATCHLIST JUN 30 2025 $CMND Clearmind Medicine Adds Hadassah-University Medical Center As New Clinical Site For Phase I/IIa Trial Evaluating CMND-100 $PLRX Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review $KLTO Klotho Neurosciences Advances KLTO-202 Gene Therapy Manufacturing To Treat ALS With Neuroprotective s-KL RNA Splice Variant $ASTS Vodafone And AST SpaceMobile Launch SatCo In Luxembourg To Pioneer Space-Based Cellular Broadband Across Europe $CME CME Group Unveils FX Tape+ To Deliver Centralized Reference Pricing From Transparent FX Marketplaces
0 · Reply
Ulong
Ulong Jun. 30 at 6:59 AM
$PLRX "Pliant Therapeutics Provides Update on BEACON-IPF" https://news.nuntiobot.com/article/319b651c-8e7f-4034-a106-7b527efae5c5
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 30 at 2:43 AM
Happy Sunday, updated gappers from Friday $VERO $GDHG $PLRX $YJ $EPRX Full watchlist out for the team, looking forward to a great week. Let's see what happened out here this weekend.
0 · Reply
BullMrketsBack
BullMrketsBack Jun. 29 at 7:19 PM
China getting hot again, Ticker YJ should be on everyone's buy list. Bottom low float, setting up for a multi-day run. YJ-Company has 74M cash on hand, $14.80 cash per share, crazy numbers! Good luck bulls. $GDHG $PLRX $HOVR $WGRX
1 · Reply
Bellbent
Bellbent Jun. 29 at 1:26 PM
$PLRX Bad news is always reported on Fridays, good news on Mondays.
0 · Reply
johncliff669
johncliff669 Jun. 28 at 6:38 PM
Top 4 Breakouts ranked by range during AH June 27th in Momentum stocks: * $VERO – $3.25 (+49%) * $PLRX – $1.40 (+12%) * $GDHG – $1.38 (+24%) * $YJ – $2.41 (+16%)
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jun. 27 at 10:23 PM
$GVH BOOM BOOM like $PLRX AND $NCPL . OFFERING CLOSED. SHORTS HAVE TO COVER.
0 · Reply
stockanalysis_
stockanalysis_ Jun. 27 at 9:47 PM
After Hours Gainers: $VERO $GDHG $NAMM $MLSS $PLRX View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply
Dr24stock
Dr24stock Jun. 27 at 9:12 PM
$PLRX short this garbage when it popped. Time to go sub1. Lets do it. Get her done.
0 · Reply
ka1954
ka1954 Jun. 27 at 9:08 PM
$PLRX too many times it tried to break 1.60-170 range. maybe this time, it will do it
0 · Reply
ka1954
ka1954 Jun. 27 at 8:37 PM
$PLRX seeing a lot big buy order 25k and so on. maybe we get somethingon monday.
0 · Reply